Outcomes4Me Inc., the developer of the main direct-to-patient, AI-driven platform remodeling the most cancers care expertise, at present introduced the shut of a $21M funding spherical.
“AI will reshape most cancers care, and this funding accelerates our means to ship personalised therapies and improved outcomes to sufferers at scale,” stated Maya R. Stated, Sc.D., Founder and CEO of Outcomes4Me. “With greater than 280,000 most cancers sufferers utilizing our AI-enabled platform, we’re not simply providing individuals identified with most cancers a device, we’re empowering them with clever, real-time insights that information them by way of each step of their care. This funding will assist us additional improve our platform, develop our attain, and drive significant income development.”
Additionally Learn: AiThority Interview with Nicole Janssen, Co-Founder and Co-CEO of AltaML
With this spherical, Outcomes4Me welcomes new investor London-based Salica Investments, with participation from all current traders: Labcorp Enterprise Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Administration Ventures, IRA Capital, and Merstal LTD, bringing Outcomes4Me’s whole capital raised so far to $38M.
AI on the Core of Most cancers Care
The way forward for most cancers care is digital, data-driven, and deeply personalised. Outcomes4Me’s AI-driven platform integrates real-time medical tips, genomic insights, treatment and symptom monitoring, medical trial matching, and affected person peer communities right into a single, easy-to-use interface for sufferers with most cancers. By combining cutting-edge AI with deep oncology experience and producing new multimodal patient-level information enriched on the drug stage, Outcomes4Me is uniquely positioned to speed up the tempo of innovation in most cancers care, driving each improved affected person outcomes and sustainable income development.
“Outcomes4Me is an AI-driven pioneer within the oncology house, scaling quickly in a market that calls for smarter, personalised healthcare options,” stated Amy Summy, Govt Vice President, Chief Advertising Officer and Client Lead for Labcorp. “We’re excited to help their digital platform as a part of our deep dedication to assist advance oncology care and enhance affected person outcomes.”
Monitor Document of Success
Outcomes4Me’s enterprise is concentrated on accelerating innovation and enhancing outcomes by partnering with life sciences firms to assist them attain the precise affected person on the proper time with the precise motion. Since its industrial launch in 2022, the corporate has been on an unbelievable income development trajectory, reflecting the rising demand for smarter, extra personalised cancer-care options. Notably, seven out of the highest 10 world most cancers pharmaceutical firms are already amongst Outcomes4Me’s valued prospects, additional demonstrating its market management.
Outcomes4Me’s innovation has been well known, producing greater than 15 trade awards previously three years, together with being named a Quick Firm World Altering Concept. Most just lately, the corporate ranked #12 on the Inc. Regionals Northeast 2025 record, leaping from #70 the earlier yr, and the 2025 EY Entrepreneur of the Yr program for the New England area named Outcomes4Me Founder and CEO Dr. Maya R. Stated a finalist. An impartial peer-reviewed research revealed in Present Oncology recognized Outcomes4Me as the very best high quality utility amongst over 3,000 purposes for adults with most cancers worldwide.
Additionally Learn: Why multimodal AI is taking up communication
Income Progress and International Growth: A Key Focus for the Future
As a part of its trajectory to turn into the main world digital well being resolution for most cancers care, Outcomes4Me is making strategic strikes towards increasing internationally with a objective to make a profound affect on world most cancers care requirements. With this new funding, Outcomes4Me will:
- Speed up its market penetration throughout a broader vary of most cancers sorts, geographies, and world markets
- Leverage its proprietary datasets and develop its AI capabilities to drive much more exact, real-time personalised therapy suggestions
- Strengthen and scale its collaborations with top-tier well being methods and life sciences firms globally
- Scale its income streams by way of new partnerships, worldwide enlargement, and revolutionary enterprise fashions
- Drive outcomes-based proof technology and real-world information insights for improved therapy and care
[To share your insights with us, please write to psen@itechseries.com]
